These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

360 related items for PubMed ID: 9205775

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Pharmacological profile of valsartan, a non-peptide angiotensin II type 1 receptor antagonist. 5th communication: hemodynamic effects of valsartan in dog heart failure models.
    Yamamoto S, Hayashi N, Kometani M, Nakao K.
    Arzneimittelforschung; 1997 May; 47(5):630-4. PubMed ID: 9205777
    [Abstract] [Full Text] [Related]

  • 4. Pharmacological profile of valsartan, a non-peptide angiotensin II type 1 receptor antagonist. 2nd communication: valsartan prevents end-organ damage in spontaneously hypertensive stroke-prone rats during 1-year treatment.
    Kometani M, Hayashi N, Yamamoto S, Nakao K, Inukai T.
    Arzneimittelforschung; 1997 May; 47(5):613-9. PubMed ID: 9205774
    [Abstract] [Full Text] [Related]

  • 5. Pharmacological profile of valsartan, a non-peptide angiotensin II type 1 receptor antagonist. 4th communication: improvement of heart failure of rats with myocardial infarction by valasartan.
    Hayashi N, Fujimura Y, Yamamoto S, Kometani M, Nakao K.
    Arzneimittelforschung; 1997 May; 47(5):625-9. PubMed ID: 9205776
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Inhibition of angiotensin I-converting enzyme with S 9490: biochemical effects, interspecies differences, and role of sodium diet in hemodynamic effects.
    Laubie M, Schiavi P, Vincent M, Schmitt H.
    J Cardiovasc Pharmacol; 1984 May; 6(6):1076-82. PubMed ID: 6084763
    [Abstract] [Full Text] [Related]

  • 9. General pharmacological properties of the new angiotensin II receptor antagonist (+/-)-1-(cyclohexyloxycarbonyloxy) ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl) biphenyl-4-yl] methyl]-1 H-benzimidazole-7-carboxylate. Part II: Effect on cardiovascular system and renal functions.
    Kito G, Ito K, Shiomi M.
    Arzneimittelforschung; 1996 Jul; 46(7):681-6. PubMed ID: 8842337
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Comparison of enalapril and valsartan in cyclosporine A-induced hypertension and nephrotoxicity in spontaneously hypertensive rats on high-sodium diet.
    Lassila M, Finckenberg P, Pere AK, Krogerus L, Ahonen J, Vapaatalo H, Nurminen ML.
    Br J Pharmacol; 2000 Jul; 130(6):1339-47. PubMed ID: 10903974
    [Abstract] [Full Text] [Related]

  • 12. [Activation of the renin-angiotensin system and blood pressure variability in rats].
    Blanc J, Lambert G, Elghozi JL.
    Arch Mal Coeur Vaiss; 2000 Aug; 93(8):1019-22. PubMed ID: 10989749
    [Abstract] [Full Text] [Related]

  • 13. Angiotensin II type 1 receptor blocker, valsartan, prevented cardiac fibrosis in rat cardiomyopathy after autoimmune myocarditis.
    Tachikawa H, Kodama M, Hui L, Yoshida T, Hayashi M, Abe S, Kashimura T, Kato K, Hanawa H, Watanabe K, Nakazawa M, Aizawa Y.
    J Cardiovasc Pharmacol; 2003 Jan; 41 Suppl 1():S105-10. PubMed ID: 12688405
    [Abstract] [Full Text] [Related]

  • 14. Effect of angiotensin II infusion with and without angiotensin II type 1 receptor blockade on nitric oxide metabolism and endothelin in human beings: a placebo-controlled study in healthy volunteers.
    Gossmann J, Burkhardt R, Harder S, Lenz T, Sedlmeyer A, Klinkhardt U, Haak T, Geiger H, Scheuermann EH.
    Clin Pharmacol Ther; 2000 Nov; 68(5):501-9. PubMed ID: 11103753
    [Abstract] [Full Text] [Related]

  • 15. Pharmacological profile of valsartan: a potent, orally active, nonpeptide antagonist of the angiotensin II AT1-receptor subtype.
    Criscione L, de Gasparo M, Bühlmayer P, Whitebread S, Ramjoué HP, Wood J.
    Br J Pharmacol; 1993 Oct; 110(2):761-71. PubMed ID: 8242249
    [Abstract] [Full Text] [Related]

  • 16. The effect of valsartan on the angiotensin II pressor response in healthy normotensive male subjects.
    Morgan JM, Palmisano M, Piraino A, Hirschhorn W, Spencer S, Prasad PP, Ortiz M, Lloyd P.
    Clin Pharmacol Ther; 1997 Jan; 61(1):35-44. PubMed ID: 9024172
    [Abstract] [Full Text] [Related]

  • 17. Effects of combined AT1 receptor antagonist/NEP inhibitor on vascular remodeling and cardiac fibrosis in SHRSP.
    Pu Q, Brassard P, Javeshghani DM, Iglarz M, Webb RL, Amiri F, Schiffrin EL.
    J Hypertens; 2008 Feb; 26(2):322-33. PubMed ID: 18192847
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Effect of valsartan on angiotensin II- and vasopressin-degrading activities in the kidney of normotensive and hypertensive rats.
    Prieto I, Martínez JM, Hermoso F, Ramírez MJ, de Gasparo M, Vargas F, Alba F, Ramírez M.
    Horm Metab Res; 2001 Sep; 33(9):559-63. PubMed ID: 11561217
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.